University of South Carolina

HIV Drugs Show Promising Potential to Reduce Alzheimer's Risk by Up to 13% Annually

15 days ago

• UVA Health researchers discovered that HIV medications called NRTIs significantly reduce Alzheimer's risk, with annual decreases of 6-13% observed across two major health insurance databases. • The protective effect appears specific to NRTIs, which block inflammasomes linked to Alzheimer's development, and could potentially prevent approximately 1 million new cases worldwide each year. • Researchers are now calling for clinical trials of both existing NRTIs and a newly developed inflammasome-blocking drug called K9, which they describe as a safer and more effective alternative.

Biophytis Presents BIO101 Obesity Program Data at SCWD International Congress, Plans Phase 2 Trial

5 months ago

• Biophytis presented its OBA program featuring BIO101 (20-hydroxyecdysone) at the 17th SCWD International Congress, highlighting its potential to mitigate muscle loss induced by GLP-1RA therapies in obese patients. • Clinical data from the Quinolia study demonstrated that 20-hydroxyecdysone reduced fat mass and maintained muscle strength in overweight and obese individuals on a hypocaloric diet. • A subgroup analysis from the SARA-INT study suggested BIO101 could improve muscle function in sarcopenic obese patients, showing statistically significant improvement in the 400-meter walking speed test. • Biophytis plans to initiate a Phase 2 OBA study in early 2025 to assess BIO101's efficacy and safety in obese patients undergoing treatment with GLP-1 RAs like Semaglutide or Wegovy.

Senex Biotechnology Receives European Patent Allowance for CDK8/19 Inhibitor SNX631-6

8 months ago

• Senex Biotechnology received a notice of allowance from the European Patent Office for SNX631-6, a selective CDK8/19 inhibitor, expanding its intellectual property portfolio. • SNX631-6 targets transcriptional reprogramming, a key process in cancer drug resistance and metastasis, showing promise across multiple cancer types. • The company plans to initiate first-in-human studies in drug-resistant metastatic cancer in 2026, following completion of IND-enabling toxicology studies. • Preclinical data indicates SNX631-6 has low nanomolar potency, high target specificity, excellent oral bioavailability, and a favorable safety profile.